Skip to main content
AAN.com

Abstract

Objective: To investigate the relationships between age-associated decreases in endogenous serum total testosterone (T) and a free T index (FTI) in men and the subsequent development of Alzheimer disease (AD).
Method: The authors used a prospective, longitudinal design with follow-up in men since 1958. Participants were from the Baltimore Longitudinal Study of Aging, a community-dwelling volunteer sample with baseline ages of 32 to 87 years. All subjects were free of AD at baseline T assessment. Five hundred seventy-four men assessed at multiple time points were followed for a mean of 19.1 years (range, 4 to 37 years). Diagnoses of AD were based on biennial physical, neurologic, and neuropsychological evaluations.
Results: Diagnosis of AD was associated inversely with FTI by itself and after adjustments for age, education, smoking status, body mass index, diabetes, any cancer diagnoses, and hormone supplements. In separate analyses, total T and sex hormone binding globulin were not significant predictors after adjustment with covariates. Increases in the FTI were associated with decreased risk of AD (hazard ratio = 0.74; 95% CI = 0.57 to 0.96), a 26% decrease for each 10-nmol/nmol FTI increase.
Conclusions: Calculated free testosterone concentrations were lower in men who developed Alzheimer disease, and this difference occurred before diagnosis. Future research may determine whether higher endogenous free testosterone levels offer protection against a diagnosis of Alzheimer disease in older men.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Sherwin BB. Estrogen and cognitive functioning in women. Proc Soc Exp Biol Med. 1998; 217: 17–22.
2.
Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory: a possible protective effect? Neurology. 1997; 49: 1491–1497.
3.
Maki P, Zonderman A, Resnick S. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry. 2001; 158: 227–233.
4.
Yaffe K, Ettinger B, Pressman A, et al. Neuropsychiatric function and dehydroepiandrosterone sulfate in elderly women: a prospective study. Biol Psychiatry. 1998; 43: 694–700.
5.
Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997; 48: 1517–1521.
6.
Becker JB, Breedlove SM, Crews D. Behavioral Endocrinology. Cambridge, MA: MIT Press, 1992.
7.
Shumaker SA, Legault C, Thal L, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289: 2651–2662.
8.
Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. Science. 1997; 278: 419–424.
9.
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001; 86: 724–731.
10.
Shute VJ, Pellegrino JW, Hubert L, Reynolds RW. The relationship between androgen levels and human spatial ability. Bull Psychonom Soc. 1983; 21: 465–468.
11.
Gouchie C, Kimura D. The relationship between testosterone levels and cognitive ability patterns. Psychoneuroendocrinology. 1991; 16: 323–334.
12.
Moffat SD, Hampson E. A curvilinear relationship between testosterone and spatial cognition in humans: possible influence of hand preference. Psychoneuroendocrinology. 1996; 21: 323–337.
13.
Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab. 1999; 84: 3681–3685.
14.
Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994; 108: 325–332.
15.
Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002; 87: 5001–5007.
16.
Hogervorst E, Williams J, Budge M, Barnetson L, Combrinck M, Smith AD. Serum total testosterone is lower in men with Alzheimer’s disease. Neuroendocrinol Lett. 2001; 22: 163–168.
17.
Shock NW, Greulich RC, Andres R, et al. Normal Human Aging: The Baltimore Longitudinal Study of Aging. Washington, DC: NIH Publication No. 84-2450, US Government Printing Office, 1984.
18.
Morley JE, Patrick P, Perry HM 3rd. Evaluation of assays available to measure free testosterone. Metabolism. 2002; 51: 554–559.
19.
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84: 3666–3672.
20.
Ware JH. Linear models for the analysis of longitudinal studies. Am Stat. 1985; 39: 95–101.
21.
Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000; 54: 2072–2077.
22.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987.
23.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984; 34: 939–944.
24.
SAS Institute Inc. SAS/STAT User’s Guide, Version 8. Cary, NC: SAS Institute Inc., 2000.
25.
Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer’s disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology. 1999; 52: 78–84.
26.
Hy LX, Keller DM. Prevalence of AD among whites: a summary by levels of severity. Neurology. 2000; 55: 198–204.
27.
Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer’s disease. JAMA. 1994; 271: 1004–1010.
28.
Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer’s disease and vascular dementia: association with education. The Rotterdam study. BMJ. 1995; 310: 970–973.
29.
Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet. 1996; 348: 429–432.
30.
Yaffe K. Hormone therapy and the brain: deja vu all over again? JAMA. 2003; 289: 2717–2719.
31.
Flood JF, Farr SA, Kaiser FE, La Regina M, Morley JE. Age-related decrease of plasma testosterone in SAMP8 mice: replacement improves age-related impairment of learning and memory. Physiol Behav. 1995; 57: 669–673.
32.
Raber J, Bongers G, LeFevour A, Buttini M, Mucke L. Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci. 2002; 22: 5204–5209.
33.
Pouliot WA, Handa RJ, Beck SG. Androgen modulates N-methyl-D-aspartate-mediated depolarization in CA1 hippocampal pyramidal cells. Synapse. 1996; 23: 10–19.
34.
Morse JK, DeKosky ST, Scheff SW. Neurotrophic effects of steroids on lesion-induced growth in the hippocampus. II. Hormone replacement. Exp Neurol. 1992; 118: 47–52.
35.
Gouras GK, Xu H, Gross RS, et al. Testosterone reduces neuronal secretion of Alzheimer’s beta-amyloid peptides. Proc Natl Acad Sci USA. 2000; 97: 1202–1205.
36.
Gandy S, Almeida OP, Fonte J, et al. Chemical andropause and amyloid-beta peptide. JAMA. 2001; 285: 2195–2196.
37.
Hammond J, Le Q, Goodyer C, Gelfand M, Trifiro M, LeBlanc A. Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem. 2001; 77: 1319–1326.
38.
Breedlove SM. Sexual differentiation of the brain and behavior. In: Becker JB, Breedlove SM, Crews D, eds. Behavioral Endocrinology. Cambridge, MA: MIT Press, 1992: 3–37.
39.
Cherrier MM, Asthana S, Plymate S, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001; 57: 80–88.
40.
Cherrier MM, Anawalt BD, Herbst KL, et al. Cognitive effects of short-term manipulation of serum sex steroids in healthy young men. J Clin Endocrinol Metab. 2002; 87: 3090–3096.
41.
Beatty WW. Gonadal hormones and sex differences in nonreproductive behaviors. In: Gerall A, Moltz H, Ward I, eds. Handbook of Behavioral Neurology. Volume II: Sexual Differentiation. New York: Plenum Press, 1992: 85–128.

Information & Authors

Information

Published In

Neurology®
Volume 62Number 2January 27, 2004
Pages: 188-193
PubMed: 14745052

Publication History

Received: May 13, 2003
Accepted: November 24, 2003
Published online: January 26, 2004
Published in print: January 27, 2004

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

S. D. Moffat, PhD
From the Laboratory of Personality and Cognition (Drs. Moffat, Zonderman, and Resnick) and Laboratory of Clinical Investigation (Dr. Metter), National Institute on Aging, Intramural Research Program, Baltimore, MD; Institute of Gerontology and Department of Psychology (Dr. Moffat), Wayne State University, Detroit, MI; Department of Neurology (Dr. Kawas), University of California, Irvine, CA; Laboratory of Clinical Investigation (Dr. Blackman), National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD; and Kronos Longevity Research Institute (Dr. Harman), Phoenix, AZ.
A. B. Zonderman, PhD
From the Laboratory of Personality and Cognition (Drs. Moffat, Zonderman, and Resnick) and Laboratory of Clinical Investigation (Dr. Metter), National Institute on Aging, Intramural Research Program, Baltimore, MD; Institute of Gerontology and Department of Psychology (Dr. Moffat), Wayne State University, Detroit, MI; Department of Neurology (Dr. Kawas), University of California, Irvine, CA; Laboratory of Clinical Investigation (Dr. Blackman), National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD; and Kronos Longevity Research Institute (Dr. Harman), Phoenix, AZ.
E. J. Metter, MD
From the Laboratory of Personality and Cognition (Drs. Moffat, Zonderman, and Resnick) and Laboratory of Clinical Investigation (Dr. Metter), National Institute on Aging, Intramural Research Program, Baltimore, MD; Institute of Gerontology and Department of Psychology (Dr. Moffat), Wayne State University, Detroit, MI; Department of Neurology (Dr. Kawas), University of California, Irvine, CA; Laboratory of Clinical Investigation (Dr. Blackman), National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD; and Kronos Longevity Research Institute (Dr. Harman), Phoenix, AZ.
C. Kawas, MD
From the Laboratory of Personality and Cognition (Drs. Moffat, Zonderman, and Resnick) and Laboratory of Clinical Investigation (Dr. Metter), National Institute on Aging, Intramural Research Program, Baltimore, MD; Institute of Gerontology and Department of Psychology (Dr. Moffat), Wayne State University, Detroit, MI; Department of Neurology (Dr. Kawas), University of California, Irvine, CA; Laboratory of Clinical Investigation (Dr. Blackman), National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD; and Kronos Longevity Research Institute (Dr. Harman), Phoenix, AZ.
M. R. Blackman, MD
From the Laboratory of Personality and Cognition (Drs. Moffat, Zonderman, and Resnick) and Laboratory of Clinical Investigation (Dr. Metter), National Institute on Aging, Intramural Research Program, Baltimore, MD; Institute of Gerontology and Department of Psychology (Dr. Moffat), Wayne State University, Detroit, MI; Department of Neurology (Dr. Kawas), University of California, Irvine, CA; Laboratory of Clinical Investigation (Dr. Blackman), National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD; and Kronos Longevity Research Institute (Dr. Harman), Phoenix, AZ.
S. M. Harman, MD PhD
From the Laboratory of Personality and Cognition (Drs. Moffat, Zonderman, and Resnick) and Laboratory of Clinical Investigation (Dr. Metter), National Institute on Aging, Intramural Research Program, Baltimore, MD; Institute of Gerontology and Department of Psychology (Dr. Moffat), Wayne State University, Detroit, MI; Department of Neurology (Dr. Kawas), University of California, Irvine, CA; Laboratory of Clinical Investigation (Dr. Blackman), National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD; and Kronos Longevity Research Institute (Dr. Harman), Phoenix, AZ.
S. M. Resnick, PhD
From the Laboratory of Personality and Cognition (Drs. Moffat, Zonderman, and Resnick) and Laboratory of Clinical Investigation (Dr. Metter), National Institute on Aging, Intramural Research Program, Baltimore, MD; Institute of Gerontology and Department of Psychology (Dr. Moffat), Wayne State University, Detroit, MI; Department of Neurology (Dr. Kawas), University of California, Irvine, CA; Laboratory of Clinical Investigation (Dr. Blackman), National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD; and Kronos Longevity Research Institute (Dr. Harman), Phoenix, AZ.

Notes

Address correspondence and reprint requests to Dr. Susan M. Resnick, National Institute on Aging, 5600 Nathan Shock Drive, Baltimore, MD 21224; e-mail: [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Androgen deprivation increases frontopolar cortical thickness in prostate cancer patients: an effect of early neurodegeneration?, American Journal of Cancer Research, 14, 7, (3652-3664), (2024).https://doi.org/10.62347/WOLA8904
    Crossref
  2. Sex and Gender Differences in Alzheimer’s Disease: Genetic, Hormonal, and Inflammation Impacts, International Journal of Molecular Sciences, 25, 15, (8485), (2024).https://doi.org/10.3390/ijms25158485
    Crossref
  3. Uncovering the Oxidative Stress Mechanisms and Targets in Alzheimer’s Disease by Integrating Phenotypic Screening Data and Polypharmacology Networks, Journal of Alzheimer's Disease, 99, s1, (S139-S156), (2024).https://doi.org/10.3233/JAD-220727
    Crossref
  4. Methods of correction of hyperprolactinemia induced by antipsychotics: current state of the problem and development prospects, V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY, 58, 2, (107-115), (2024).https://doi.org/10.31363/2313-7053-2024-972
    Crossref
  5. Low testosterone levels relate to poorer cognitive function in women in an APOE-ε4-dependant manner, Biology of Sex Differences, 15, 1, (2024).https://doi.org/10.1186/s13293-024-00620-4
    Crossref
  6. The relationship between male and female endogenous reproductive hormones levels and subjective cognitive decline score: A cross‐sectional analysis of the Pingyin cohort study, Clinical Endocrinology, (2024).https://doi.org/10.1111/cen.15104
    Crossref
  7. Effect of hormone therapy on personality traits: preliminary evidence in older men and women, Climacteric, (1-8), (2024).https://doi.org/10.1080/13697137.2024.2393128
    Crossref
  8. Association between probable sarcopenia and dementia risk: a prospective cohort study with mediation analysis, Translational Psychiatry, 14, 1, (2024).https://doi.org/10.1038/s41398-024-03131-3
    Crossref
  9. Sex Differences in Alzheimer’s Disease Pathogenesis, Sex/Gender-Specific Medicine in Clinical Areas, (403-421), (2024).https://doi.org/10.1007/978-981-97-0130-8_24
    Crossref
  10. Sex/Gender Differences in Dementia and Alzheimer’s Disease, Sex/Gender-Specific Medicine in Clinical Areas, (391-401), (2024).https://doi.org/10.1007/978-981-97-0130-8_23
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share